XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 28, 2021 $ 131,449 $ 124,684,535 $ (124,861,827) $ (45,843)
Balance (in shares) at Feb. 28, 2021 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   84,967   84,967
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   215,926   215,926
Net loss     (316,283) (316,283)
Balance at May. 31, 2021 $ 131,449 124,985,428 (125,178,110) (61,233)
Balance (in shares) at May. 31, 2021 131,448,444      
Balance at Feb. 28, 2022 $ 131,449 125,708,240 (125,838,483) 1,206
Balance (in shares) at Feb. 28, 2022 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   40,517   40,517
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   151,334   151,334
Net loss     (231,737) (231,737)
Balance at May. 31, 2022 $ 131,449 $ 125,900,091 $ (126,070,220) $ (38,680)
Balance (in shares) at May. 31, 2022 131,448,444